ReviewFrontiers in immunology2026
Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence constitutes the core biological basis of body aging. It not only directly drives the occurrence and progression of multiple age-related diseases, but also establishes and maintains a chronic inflammatory microenvironment through the senescence-associated secretory phenotype (SASP), thereby continuously exacerbating tissue functional decline. In recent years, CAR-T cell therapy, as the first revolutionary therapy in cancer immunotherapy, has opened up new ways to intervene in age-related diseases with its excellent target elimination capabilities. This article first studies the molecular mechanisms of cellular senescence and its pathological effects. Then a systematic overview of the design principles, development trajectory and current applications of CAR-T technology is given, focusing on the latest experimental and clinical advances in aging-related cancers, neurodegenerative diseases and cardiovascular diseases. We also dive into key current challenges, including immune-senescence, target reliability, and treatment safety. Finally, we will explore the future optimization direction of CAR-T therapy and its translational potential through various strategies such as engineered immune cells and combination therapy, hoping to provide valuable insights into research and clinical practice in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.